ClinicalTrials.gov record
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

ClinicalTrials.gov ID: NCT07007793

Public ClinicalTrials.gov record NCT07007793. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 22, 2026, 8:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism

Study identification

NCT ID
NCT07007793
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
250 participants

Conditions and interventions

Interventions

  • Baxdrostat Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 6, 2025
Primary completion
Feb 17, 2028
Completion
Feb 17, 2028
Last update posted
Apr 19, 2026

2025 – 2028

United States locations

U.S. sites
21
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Research Site Los Angeles California 90048 Not yet recruiting
Research Site San Francisco California 94110 Not yet recruiting
Research Site Farmington Connecticut 06030 Not yet recruiting
Research Site Chicago Illinois 60611 Not yet recruiting
Research Site Springfield Illinois 62702 Recruiting
Research Site Baltimore Maryland 21287 Not yet recruiting
Research Site Boston Massachusetts 02111 Recruiting
Research Site Boston Massachusetts 02115 Recruiting
Research Site Ann Arbor Michigan 48109 Recruiting
Research Site Rochester Minnesota 55902 Recruiting
Research Site Olive Branch Mississippi 38654 Recruiting
Research Site Kansas City Missouri 64151 Withdrawn
Research Site New York New York 10065 Not yet recruiting
Research Site Cleveland Ohio 44195 Not yet recruiting
Research Site Columbus Ohio 43210 Recruiting
Research Site Portland Oregon 97239 Withdrawn
Research Site Bethlehem Pennsylvania 18017 Recruiting
Research Site Philadelphia Pennsylvania 19104 Not yet recruiting
Research Site Columbia South Carolina 29203 Recruiting
Research Site Brownsville Texas 78526 Withdrawn
Research Site Dallas Texas 75390 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 68 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07007793, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 19, 2026 · Synced Apr 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07007793 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →